ATNM: Actinium Pharmaceuticals, Inc.
About
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.
Current Value
$1.471 Year Return
Current Value
$1.471 Year Return
Key Details
Market Cap
$45.86M
P/E Ratio
-1.05
1Y Stock Return
-66.74%
1Y Revenue Growth
80.00%
Dividend Yield
0.00%
Price to Book
1.2
Strategies that include ATNM
Stock's related to ATNM
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| GBIO | 46.66% | $88.17M | +14.78% | 0.00% |
| PGEN | 43.82% | $259.78M | -20.80% | 0.00% |
| XNCR | 39.70% | $1.69B | +28.67% | 0.00% |
| NCMI | 39.07% | $646.37M | +63.31% | 0.00% |
| TY | 39.05% | - | - | 3.31% |
| HCAT | 38.69% | $466.09M | -0.78% | 0.00% |
| ENTA | 38.42% | $197.27M | +3.56% | 0.00% |
| LYTS | 37.31% | $603.63M | +52.68% | 0.98% |
| JOUT | 37.02% | $331.43M | -37.82% | 4.03% |
| CRNX | 36.99% | $5.29B | +85.52% | 0.00% |
| ELVN | 36.78% | $1.24B | +122.89% | 0.00% |
| PTMN | 35.87% | - | - | 16.24% |
| ALDX | 35.85% | $286.43M | +90.12% | 0.00% |
| GMAB | 35.59% | $13.00B | -35.12% | 0.00% |
| AMRX | 35.43% | $2.58B | +86.97% | 0.00% |
| STHO | 35.19% | $149.31M | -8.49% | 0.00% |
| GPRO | 35.08% | $184.94M | -66.20% | 0.00% |
| KRYS | 35.04% | $5.24B | +78.68% | 0.00% |
| ATR | 34.91% | $11.30B | +32.13% | 1.01% |
| ODP | 33.95% | $802.05M | -45.22% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NHTC | 0.12% | $64.47M | +3.99% | 13.82% |
| CME | -0.21% | $81.64B | +7.34% | 2.00% |
| COR | -0.28% | $48.41B | +23.04% | 0.84% |
| QNTM | -0.36% | $9.47M | -94.01% | 0.00% |
| IMNN | -0.37% | $10.05M | -22.14% | 0.00% |
| AGRO | -0.45% | $1.15B | -2.12% | 3.10% |
| BROS | -0.48% | $5.93B | +80.24% | 0.00% |
| PAC | 0.49% | $8.06B | +28.66% | 0.00% |
| SHOP | 0.49% | $137.54B | +50.06% | 0.00% |
| JNPR | -0.50% | $11.73B | +31.03% | 2.48% |
| CLLS | -0.55% | $134.09M | -34.04% | 0.00% |
| SMR | -0.60% | $2.80B | +976.65% | 0.00% |
| CCEC | -0.60% | $1.03B | +31.48% | 3.19% |
| CYCN | -0.65% | $3.85M | -33.95% | 0.00% |
| LMT | 0.66% | $128.48B | +20.34% | 2.32% |
| VIRT | 0.67% | $3.25B | +113.85% | 2.55% |
| ABEV | 0.72% | $33.82B | -22.10% | 6.97% |
| CI | -0.76% | $91.81B | +14.48% | 1.65% |
| CLX | 0.82% | $20.94B | +20.38% | 2.86% |
| BACK | 0.86% | $1.93M | -32.12% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| K | -25.88% | $27.93B | +52.93% | 2.77% |
| XGN | -16.20% | $69.14M | +151.28% | 0.00% |
| HUSA | -14.77% | $18.58M | -19.77% | 0.00% |
| SAVA | -9.72% | $1.55B | +51.22% | 0.00% |
| FTNT | -9.69% | $72.06B | +77.50% | 0.00% |
| PRPO | -9.13% | $8.89M | -14.59% | 0.00% |
| LUMO | -8.05% | $37.45M | +40.58% | 0.00% |
| CBOE | -6.83% | $22.09B | +17.17% | 1.08% |
| STG | -6.81% | $35.47M | +5.43% | 0.00% |
| DASH | -6.73% | $71.93B | +81.62% | 0.00% |
| BBD | -6.36% | $12.66B | -19.27% | 1.65% |
| CRVO | -5.95% | $79.07M | -3.91% | 0.00% |
| DT | -5.85% | $15.66B | +1.06% | 0.00% |
| CHD | -5.81% | $27.50B | +19.29% | 1.01% |
| INSP | -5.44% | $5.58B | +29.21% | 0.00% |
| BBDO | -5.39% | $11.53B | -17.08% | 1.69% |
| ZTO | -4.50% | $11.85B | -10.80% | 4.98% |
| FATBB | -3.93% | $75.27M | -12.35% | 12.73% |
| GRAL | -3.71% | $508.58M | -3.65% | 0.00% |
| BTCT | -3.01% | $58.86M | +395.83% | 0.00% |
ETF's related to ATNM
News
Yahoo
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today highlighted recent regulatory and development updates for its Iomab-B, Actimab-A and Iomab-ACT ARC clinical programs as well as its financial results for the third quarter ended September 30, 2024. Iomab-B is a first in class CD45 targeted conditioning agent to enable bone marrow transplant (BMT) and has been
Yahoo
NEW YORK (AP) — Actinium Pharmaceuticals Inc. ATNM) on Thursday reported a loss of $11.6 million in its third quarter. On a per-share basis, the New York-based company said it had a loss of 37 cents.
Finnhub
NEW YORK - Actinium Pharmaceuticals, Inc. , a leader in the development of Antibody Radiation Conjugates and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D.,...
Finnhub
NEW YORK, Sept. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. . Such investors are advised to contact Danielle Peyton at...
Finnhub
NEW YORK - Actinium Pharmaceuticals, Inc. , a leader in the development of Antibody Radiation Conjugates and other targeted radiotherapies, today announced the publication of the Phase 3 SIERRA...
Yahoo
According to the findings, the trial met its primary endpoint of durable complete remission.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.